Insider Selling: Dermira, Inc. (DERM) Director Sells 500 Shares of Stock
Dermira, Inc. (NASDAQ:DERM) Director William R. Ringo sold 500 shares of Dermira stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $32.00, for a total value of $16,000.00. Following the completion of the transaction, the director now owns 500 shares in the company, valued at approximately $16,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Dermira, Inc. (NASDAQ:DERM) opened at 33.24 on Friday. The firm’s market cap is $1.18 billion. Dermira, Inc. has a one year low of $17.42 and a one year high of $36.34. The company has a 50-day moving average price of $29.74 and a 200-day moving average price of $31.79.
This article was posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The legal version of this article can be read at http://www.dailypolitical.com/2017/02/17/insider-selling-dermira-inc-derm-director-sells-500-shares-of-stock.html.
Several large investors have recently made changes to their positions in DERM. FMR LLC increased its stake in shares of Dermira by 10.1% in the fourth quarter. FMR LLC now owns 4,710,737 shares of the biopharmaceutical company’s stock worth $142,877,000 after buying an additional 433,601 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock worth $72,877,000 after buying an additional 1,101,645 shares during the period. BlackRock Fund Advisors increased its stake in shares of Dermira by 10.8% in the third quarter. BlackRock Fund Advisors now owns 1,325,981 shares of the biopharmaceutical company’s stock worth $44,845,000 after buying an additional 129,437 shares during the period. Great Point Partners LLC bought a new stake in shares of Dermira during the third quarter worth approximately $22,977,000. Finally, BlackRock Advisors LLC increased its stake in shares of Dermira by 9.3% in the third quarter. BlackRock Advisors LLC now owns 459,211 shares of the biopharmaceutical company’s stock worth $15,531,000 after buying an additional 39,023 shares during the period. Institutional investors own 84.92% of the company’s stock.
A number of brokerages recently weighed in on DERM. SEB Equity Research reiterated a “reduce” rating on shares of Dermira in a report on Tuesday, January 3rd. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Dermira currently has a consensus rating of “Buy” and a consensus price target of $41.00.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.